Floatz logo

FLUOXETINE

Visual Field Loss

Bogachan SahinSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Visual Field Loss cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
University Hospital Freiburg
Phase 3B
Humax-Cd20
Johns Hopkins University
D
LEVODOPA
Qilu Hospital of Shandong University
N/AD
Sepofarsen
Laboratoires Thea
Phase 3NR

Same molecule, other indications

FLUOXETINE is also rated in:

depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
anxiety disorderDormant
BBB
Indicative ·
74 / 100
View asset →
mood disorderDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →